Clinical Trial Update: Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation [Phase 4]

View source ↗

Summary

Phase 4 trial update shows tocilizumab can induce remission in rheumatoid arthritis and may maintain efficacy after discontinuation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: SURPRISE Study Group | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED